💊FDA Workshop on Patient Experience Data and Drug Development
Patient-Focused Drug Development: Workshop #2 To Discuss Methodologic and Other Challenges Related to Patient Experience Data; Public Workshop; Request for Comments
Summary
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Patient-Focused Drug Development: Workshop #2 to Discuss Methodologic and Other Challenges Related to Patient Experience Data." The purpose of the public workshop is to discuss methodological challenges related to patient experience data, and other areas of greatest interest or concern to public stakeholders.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$$ - High
The regulatory notice involves a public workshop discussing patient experience data, which has direct implications for pharmaceutical companies and healthcare businesses. The FDA is seeking input from stakeholders to better inform drug development and regulatory decision-making, indicating a shift that could affect compliance and product strategies.